Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge J Castillo

Showing results (311-320 of 343) with videos related to

Pageof 35
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2019
Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaMark Bustoros, Romanos Sklavenitis-Pistofidis, Prashant Kapoor, et al.
The New England Journal of Medicine|April 9, 2015
Ibrutinib in previously treated Waldenström's macroglobulinemiaSteven P Treon, Christina K Tripsas, Kirsten Meid, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2020
A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL)Brady E Beltrán, Luis Villela, Maria A Torres, et al.
Blood Advances|March 15, 2022
High frequency of central nervous system involvement in transformed Waldenström macroglobulinemiaEric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Blood Advances|January 7, 2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 8, 2019
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020Shaji K Kumar, Natalie S Callander, Jens Hillengass, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 1 from the 11<sup>th</sup> International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patientsChristian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, et al.
Pageof 35

Showing results (311-320 of 343) with videos related to

Sort By:
Pageof 35
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2019
Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaMark Bustoros, Romanos Sklavenitis-Pistofidis, Prashant Kapoor, et al.
The New England Journal of Medicine|April 9, 2015
Ibrutinib in previously treated Waldenström's macroglobulinemiaSteven P Treon, Christina K Tripsas, Kirsten Meid, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2020
A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL)Brady E Beltrán, Luis Villela, Maria A Torres, et al.
Blood Advances|March 15, 2022
High frequency of central nervous system involvement in transformed Waldenström macroglobulinemiaEric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Blood Advances|January 7, 2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 8, 2019
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020Shaji K Kumar, Natalie S Callander, Jens Hillengass, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 1 from the 11<sup>th</sup> International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patientsChristian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, et al.
Pageof 35